Drug Trial News RSS Feed - Drug Trial News

NIAID begins early-stage trial of experimental vaccine for preventing yellow fever virus

NIAID begins early-stage trial of experimental vaccine for preventing yellow fever virus

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has begun an early-stage clinical trial of an investigational vaccine designed to protect against yellow fever virus. [More]
Duke to lead early-stage clinical trials for promising new neurological therapies

Duke to lead early-stage clinical trials for promising new neurological therapies

Duke University could receive up to $19 million to lead early-stage clinical trials for new drugs to treat neurological conditions such as Alzheimer's disease and neuropathy. [More]
Pulmatrix announces positive results from Phase 1 study of novel dry powder formulation in COPD patients

Pulmatrix announces positive results from Phase 1 study of novel dry powder formulation in COPD patients

Pulmatrix, Inc., today announced positive topline data from a Phase 1 pilot pharmacokinetic bioavailability trial of PUR0200. PUR0200 is a novel dry powder formulation of a currently marketed once daily bronchodilator, formulated in the company's proprietary iSPERSETM dry powder delivery technology. [More]
Adding new monoclonal antibody to chemotherapy improves survival in soft-tissue sarcoma patients

Adding new monoclonal antibody to chemotherapy improves survival in soft-tissue sarcoma patients

Adding a novel monoclonal antibody therapy to traditional chemotherapy increased median survival by nearly a year in patients with advanced sarcoma, a lethal soft-tissue cancer. [More]
Study highlights effectiveness of atypical antipsychotic drug in treating children with TD

Study highlights effectiveness of atypical antipsychotic drug in treating children with TD

A meta-analysis of clinical trials evaluating the effectiveness of aripiprazole for the treatment of Tourette's disorder (TD) in children and adolescents showed a significantly greater overall improvement in total tics and tic severity from pretreatment to post-treatment for the aripiprazole compared to the placebo group. [More]
Study reports BV therapy may be curative in some Hodgkin lymphoma patients

Study reports BV therapy may be curative in some Hodgkin lymphoma patients

Five-year survival data published online today in Blood, the Journal of the American Society of Hematology, suggest that the targeted therapy brentuximab vedotin may have cured some Hodgkin lymphoma patients whose disease has persisted despite receiving previous therapies. [More]
Phase III clinical study of promising prostate cancer drug reveals surprising results

Phase III clinical study of promising prostate cancer drug reveals surprising results

A recently published international clinical Phase III trial of a promising drug for treating advanced prostate cancer ended with surprising results: the new therapeutic agent failed to achieve any significant improvement in the overall survival of patients compared with the established standard treatment. [More]
Leukemia drug increases brain dopamine, lowers toxic proteins linked to Parkinson's or dementia

Leukemia drug increases brain dopamine, lowers toxic proteins linked to Parkinson's or dementia

A small phase I study provides molecular evidence that an FDA-approved drug for leukemia significantly increased brain dopamine and reduced toxic proteins linked to disease progression in patients with Parkinson's disease or dementia with Lewy bodies. [More]
New data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator product

New data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator product

Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced results from the EGALITY trial in which the primary endpoint of achieving equivalence in Psoriasis Area and Severity Index (PASI) 75 response rates at week 12 was met. [More]
Clinical trial to test low-dose heparin treatment for patients with ruptured brain aneurysm

Clinical trial to test low-dose heparin treatment for patients with ruptured brain aneurysm

A Louisville patient is the first to be enrolled in a national clinical trial to test a new treatment for patients who have suffered a ruptured brain aneurysm. [More]
Clinical trial to evaluate safety of palbociclib drug in African American women with breast cancer

Clinical trial to evaluate safety of palbociclib drug in African American women with breast cancer

The first clinical trial to test a newly approved breast cancer drug specifically in African American patients is now enrolling at Georgetown Lombardi Comprehensive Cancer Center and will begin soon at five other institutions in Washington, DC, Maryland, Alabama and New Jersey. [More]
European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

Amgen has announced that the European Commission (EC) has approved a variation to the marketing authorization for KyprolisĀ® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. The extended indication marks the second approval for Kyprolis by the EC in less than a year. [More]
MorphoSys receives clinical milestone for start of Phase 1 trial in prevention of thrombosis with novel antibody

MorphoSys receives clinical milestone for start of Phase 1 trial in prevention of thrombosis with novel antibody

MorphoSys AG announced that it has received a milestone payment from Novartis in connection with the initiation of a clinical phase 1 trial with a novel HuCAL antibody. The antibody will be tested in the field of prevention of thrombosis. This is the twelfth therapeutic antibody based on MorphoSys's technologies that Novartis is evaluating in clinical trials. Financial details were not disclosed. [More]
Quantum Genomics initiates Phase IIa trial for heart failure

Quantum Genomics initiates Phase IIa trial for heart failure

Quantum Genomics, a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced the initiation of its Phase IIa multicentric clinical trial of GQC101, entitled QUID HF (QUantum Genomics Incremental Dosing in Heart Failure), for the treatment of patients with chronic heart failure. The first three clinical centres of the European trial have been opened in France and Norway. [More]
Deutetrabenazine may help improve chorea symptoms in patients with HD

Deutetrabenazine may help improve chorea symptoms in patients with HD

People with Huntington disease (HD) experienced improvements in chorea while taking deutetrabenazine (SD-809) compared to placebo, according to a paper published today in the Journal of the American Medical Association. [More]
TAILOR study shows treatment with Erbitux plus FOLFOX improves survival in RAS wild-type mCRC patients

TAILOR study shows treatment with Erbitux plus FOLFOX improves survival in RAS wild-type mCRC patients

Merck, a leading science and technology company, will present data at the ESMO 18th World Congress on Gastrointestinal Cancer from the pivotal Phase III TAILOR study in patients from China, the first prospective trial to evaluate an anti-EGFR antibody in the first-line therapy of patients with RAS wild-type metastatic colorectal cancer (mCRC). [More]
Novel anti-interleukin 1-alpha antibody shows promise in treating advanced colorectal cancer patients

Novel anti-interleukin 1-alpha antibody shows promise in treating advanced colorectal cancer patients

A novel anti-interleukin 1-alpha antibody has shown a significant impact on symptoms, and a high level of safety and tolerability in patients with advanced colorectal cancer, according to phase III data presented at the European Society for Medical Oncology's 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain. [More]
Regorafenib drug improves survival rates in patients with hepatocellular carcinoma

Regorafenib drug improves survival rates in patients with hepatocellular carcinoma

Oral multikinase inhibitor regorafenib achieves significantly improved survival rates compared to placebo in patients with hepatocellular carcinoma, according to data from the phase III RESORCE trial, presented at the ESMO 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain. [More]
Epclusa drug receives FDA approval for treating adult patients with chronic HCV

Epclusa drug receives FDA approval for treating adult patients with chronic HCV

The U.S. Food and Drug Administration approved Epclusa to treat adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis (advanced liver disease). [More]
Novel combination therapy slows cancer growth in patients with advanced solid tumors

Novel combination therapy slows cancer growth in patients with advanced solid tumors

A phase 1 clinical trial testing a novel combination therapy developed by scientists at VCU Massey Cancer Center slowed the growth of cancer in the majority of trial participants, which were patients with advanced solid tumors. [More]
Advertisement
Advertisement